Home › Funds › OAKTREE CAPITAL MANAGEMENT LP › BMRN

OAKTREE CAPITAL MANAGEMENT LP position in BMRN

BIOMARIN PHARMACEUTICAL INC COM · Health Care

OAKTREE CAPITAL MANAGEMENT LP reported holding 64,025,000 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q2 2026 13F filing — a position valued at US$62.4M, representing 0.91% of its reported portfolio and ranking #20 among its reported holdings. OAKTREE CAPITAL MANAGEMENT LP has disclosed BMRN holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)64.03M sh
Reported value held$62.37M
Portfolio Weight0.91%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How OAKTREE CAPITAL MANAGEMENT LP's BMRN position evolved

OAKTREE CAPITAL MANAGEMENT LP first disclosed a stake in BMRN in Q4 2023 at 7,867,000 shares (US$7.8M). The position peaked in Q2 2026 at 64,025,000 shares, worth US$62.4M. Across 7 filings, OAKTREE CAPITAL MANAGEMENT LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 64,025,000 shares valued at US$62.4M — an increase of 8,040,000 shares quarter over quarter.. Notable position changes include a 1231% increase in Q3 2025 (shares rose 10% over the following quarter), a 114% increase in Q4 2025 (shares fell 5% over the following quarter), a 33% increase in Q1 2026 (shares rose 1% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 7.87M $7.77M New
Q2 2024 2.94M $2.92M New
Q2 2025 1.48M $1.40M New
Q3 2025 19.72M $18.74M Add
Q4 2025 42.12M $40.45M Add
Q1 2026 55.98M $54.02M Add
Q2 2026 64.03M $62.37M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BMRN and 13F data

BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BMRN

All BMRN fund holders →

FAQ

How long has OAKTREE CAPITAL MANAGEMENT LP held BMRN?

OAKTREE CAPITAL MANAGEMENT LP has disclosed BMRN holdings in 7 of the last 11 reported quarters, going back to Q4 2023.

What is OAKTREE CAPITAL MANAGEMENT LP's current position in BMRN?

As of Q2 2026, OAKTREE CAPITAL MANAGEMENT LP holds 64.03M shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $62.37M, representing 0.91% of its reported portfolio and ranking #20.

Has OAKTREE CAPITAL MANAGEMENT LP been buying or selling BMRN?

In the latest 13F filing (Q2 2026), OAKTREE CAPITAL MANAGEMENT LP increased its position in BMRN. The position peaked in Q2 2026 at 64.03M shares.

Which other funds hold BMRN?

Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.